MarketPeel
Insider Trading Intelligence
Pricing
…
SB

Sarah Boyce

OABI
DIRECTOR · OMNIAB, INC. · CIK 0001629383
FILING MIX · LIFETIME49%/51%
BUYS
58
SELLS
60
TOTAL VALUE
$35.32M
COMPANIES
5
ACTIVE SINCE
Jun 2020
HOLDINGS NOW
41,892
AVG SELL PX
$34.44
TRADE KIND
SHOWING 118 / 118
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
2 backtested trades · 8 horizonsHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Sarah Boyce, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d2+0.00%-8.27%+2.79%-11.06%-11.06%—
14d2+50.00%-2.92%+4.76%-7.68%-7.68%—
30d2+100.00%+23.09%+2.38%+20.71%+20.71%—
60d2+100.00%+20.31%+1.43%+18.88%+18.88%—
90d2+100.00%+38.72%+8.00%+30.72%+30.72%—
180d2+100.00%+19.45%+8.12%+11.33%+11.33%—
1y2+100.00%+49.18%+15.59%+33.59%+33.59%—
2y2+100.00%+56.72%+60.31%-3.60%-3.60%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
OABI · 0 shares · as of Jun 18, 2024
017,09534,19151,28668,38120232024SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 58 buys / 60 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
CTNM
CONTINEUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
19,000——19,000Jun 26, 2026Jun 26, 2026 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,000——20,000Feb 27, 2026Mar 2, 2026 ↗View →
RNAM
AVIDITY BIOSCIENCES, INC.
SALE
President and CEO
300,000——0Feb 27, 2026Feb 27, 2026 ↗View →
RNAM
AVIDITY BIOSCIENCES, INC.
SALE
President and CEO
425,000——0Feb 27, 2026Feb 27, 2026 ↗View →
RNAM
AVIDITY BIOSCIENCES, INC.
SALE
President and CEO
200,000——0Feb 27, 2026Feb 27, 2026 ↗View →
RNAM
AVIDITY BIOSCIENCES, INC.
SALE
President and CEO
386,015——0Feb 27, 2026Feb 27, 2026 ↗View →
RNAM
AVIDITY BIOSCIENCES, INC.
SALE
President and CEO
165,000——0Feb 27, 2026Feb 27, 2026 ↗View →
RNAM
AVIDITY BIOSCIENCES, INC.
SALE
President and CEO
400,000——0Feb 27, 2026Feb 27, 2026 ↗View →
RNAM
AVIDITY BIOSCIENCES, INC.
SALE
President and CEO
474,861——0Feb 27, 2026Feb 27, 2026 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
6,394$72.45$463.2K277,000Jan 21, 2026Jan 23, 2026 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
7,993$72.45$579.1K269,007Jan 21, 2026Jan 23, 2026 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
8,576$72.23$619.4K283,394Jan 7, 2026Jan 9, 2026 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALEGRANT
Gift
29,159——291,970Dec 18, 2025Dec 19, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
31,000——336,871Dec 17, 2025Dec 19, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
President and CEO
15,742$71.87$1.13M321,129Dec 17, 2025Dec 19, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
President and CEO
50,000——1,022,015Sep 5, 2025Sep 5, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
President and CEO
50,000$1.24$62.0K355,871Sep 5, 2025Sep 5, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
50,000$49.95$2.50M305,871Sep 5, 2025Sep 5, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
25,000$49.39$1.23M305,871Aug 28, 2025Aug 29, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
President and CEO
25,000$1.24$31.0K330,871Aug 28, 2025Aug 29, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
President and CEO
25,000——1,072,015Aug 28, 2025Aug 29, 2025 ↗View →
CTNM
CONTINEUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
14,750——14,750Jun 26, 2025Jun 26, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
31,540$31.06$979.6K305,871Mar 20, 2025Mar 21, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
4,738$28.59$135.5K343,070Jan 21, 2025Jan 23, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
5,659$28.59$161.8K337,411Jan 21, 2025Jan 23, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
165,000——165,000Jan 6, 2025Jan 8, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
82,500——347,808Jan 6, 2025Jan 8, 2025 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
31,855$32.66$1.04M265,308Dec 18, 2024Dec 19, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
32,880$44.00$1.45M234,663Sep 23, 2024Sep 23, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
62,500——297,163Sep 19, 2024Sep 23, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
62,500——267,543Sep 19, 2024Sep 23, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
President and CEO
28,000——461,015Aug 6, 2024Aug 7, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
28,000$43.35$1.21M205,043Aug 6, 2024Aug 7, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
President and CEO
28,000$1.24$34.7K233,043Aug 6, 2024Aug 7, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
28,000$39.93$1.12M205,043Jul 9, 2024Jul 11, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
President and CEO
28,000$1.24$34.7K233,043Jul 9, 2024Jul 11, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
President and CEO
28,000——489,015Jul 9, 2024Jul 11, 2024 ↗View →
CTNM
CONTINEUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
29,500——29,500Jun 24, 2024Jun 24, 2024 ↗View →
OABI
OMNIAB, INC.
PURCHASE
20,000——68,381Jun 18, 2024Jun 20, 2024 ↗View →
OABI
OMNIAB, INC.
PURCHASEGRANT
Stock grant
40,000——40,000Jun 18, 2024Jun 20, 2024 ↗View →
OABI
OMNIAB, INC.
PURCHASEGRANT
Stock grant
20,000——20,000Jun 18, 2024Jun 20, 2024 ↗View →
OABI
OMNIAB, INC.
SALE
20,000——0Jun 18, 2024Jun 20, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
32,074$39.13$1.26M142,543Jun 18, 2024Jun 20, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
62,500——174,617Jun 17, 2024Jun 20, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
62,500——205,043Jun 17, 2024Jun 20, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
35,767$40.08$1.43M112,117Jun 14, 2024Jun 14, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
President and CEO
35,767——517,015Jun 14, 2024Jun 14, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
President and CEO
35,767$1.24$44.4K147,884Jun 14, 2024Jun 14, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
President and CEO
164,233$1.24$203.6K276,350Jun 13, 2024Jun 14, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
President and CEO
164,233——552,782Jun 13, 2024Jun 14, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
164,233$40.08$6.58M112,117Jun 13, 2024Jun 14, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
100,000$35.73$3.57M112,117Jun 12, 2024Jun 14, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
President and CEO
100,000$1.24$124.0K212,117Jun 12, 2024Jun 14, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
President and CEO
100,000——717,015Jun 12, 2024Jun 14, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
President and CEO
28,000$1.24$34.7K140,117Jun 4, 2024Jun 5, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
President and CEO
28,000——817,015Jun 4, 2024Jun 5, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
28,000$27.42$767.8K112,117Jun 4, 2024Jun 5, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
President and CEO
28,000$1.24$34.7K140,117May 7, 2024May 7, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
28,000$25.54$715.0K112,117May 7, 2024May 7, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
President and CEO
28,000——845,015May 7, 2024May 7, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
28,000$26.25$734.9K112,117Apr 2, 2024Apr 3, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
President and CEO
28,000——873,015Apr 2, 2024Apr 3, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
President and CEO
28,000$1.24$34.7K140,117Apr 2, 2024Apr 3, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
President and CEO
28,000$1.24$34.7K140,117Mar 12, 2024Mar 12, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
28,000$22.63$633.7K112,117Mar 12, 2024Mar 12, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
President and CEO
28,000——901,015Mar 12, 2024Mar 12, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
84,000$21.39$1.80M112,117Mar 8, 2024Mar 12, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
President and CEO
84,000$1.24$104.2K196,117Mar 8, 2024Mar 12, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
President and CEO
84,000——929,015Mar 8, 2024Mar 12, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
President and CEO
84,000——1,013,015Mar 1, 2024Mar 5, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
President and CEO
84,000$1.24$104.2K196,117Mar 1, 2024Mar 5, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
84,000$20.13$1.69M112,117Mar 1, 2024Mar 5, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
5,092$10.13$51.6K44,008Jan 22, 2024Jan 23, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
62,500——67,209Jan 20, 2024Jan 23, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
300,000——300,000Jan 20, 2024Jan 23, 2024 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
200,000——200,000Sep 11, 2023Sep 12, 2023 ↗View →
OABI
OMNIAB, INC.
PURCHASEGRANT
Stock grant
20,000——20,000Jun 23, 2023Jun 27, 2023 ↗View →
OABI
OMNIAB, INC.
PURCHASEGRANT
Stock grant
40,000——40,000Jun 23, 2023Jun 27, 2023 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
President and CEO
3,221——1,097,015Feb 3, 2023Feb 3, 2023 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
President and CEO
3,221$24.26$78.1K53,352Feb 3, 2023Feb 3, 2023 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
President and CEO
3,221$1.24$4.0K56,573Feb 3, 2023Feb 3, 2023 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
President and CEO
45,879$1.24$56.9K99,231Feb 2, 2023Feb 3, 2023 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
President and CEO
45,879$24.36$1.12M53,352Feb 2, 2023Feb 3, 2023 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
President and CEO
45,879——1,100,236Feb 2, 2023Feb 3, 2023 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
President and CEO
900$1.24$1.1K54,252Feb 1, 2023Feb 3, 2023 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
President and CEO
900——1,146,115Feb 1, 2023Feb 3, 2023 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
President and CEO
900$24.27$21.8K53,352Feb 1, 2023Feb 3, 2023 ↗View →
OABI
OMNIAB, INC.
PURCHASEGRANT
Stock grant
8,753——46,190Jan 30, 2023Feb 1, 2023 ↗View →
OABI
OMNIAB, INC.
PURCHASEGRANT
Stock grant
37,840——37,840Jan 30, 2023Feb 1, 2023 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
50,000——53,352Jan 20, 2023Jan 24, 2023 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
400,000——400,000Jan 20, 2023Jan 24, 2023 ↗View →
OABI
OMNIAB, INC.
PURCHASE
15,000$2.92$43.8K36,000Nov 10, 2022Nov 14, 2022 ↗View →
OABI
OMNIAB, INC.
PURCHASE
21,000$2.74$57.6K21,000Nov 9, 2022Nov 14, 2022 ↗View →
OABI
OMNIAB, INC.
PURCHASEGRANT
Stock grant
13,994——13,994Nov 1, 2022Nov 3, 2022 ↗View →
OABI
OMNIAB, INC.
PURCHASEGRANT
Stock grant
10,565——10,565Nov 1, 2022Nov 3, 2022 ↗View →
OABI
OMNIAB, INC.
PURCHASEGRANT
Stock grant
37,840——37,840Nov 1, 2022Nov 3, 2022 ↗View →
OABI
OMNIAB, INC.
PURCHASEGRANT
Stock grant
39,628——48,381Nov 1, 2022Apr 23, 2024 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
SALE
4,340——0Nov 1, 2022Nov 3, 2022 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
SALE
1,004——2,892Nov 1, 2022Nov 3, 2022 ↗View →
OABI
OMNIAB, INC.
PURCHASEGRANT
Stock grant
37,437——37,437Nov 1, 2022Nov 3, 2022 ↗View →
OABI
OMNIAB, INC.
PURCHASEGRANT
Stock grant
22,616——22,616Nov 1, 2022Nov 3, 2022 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
President and CEO
14,855$1.24$18.4K14,855Aug 25, 2022Aug 26, 2022 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
President and CEO
14,855——1,147,015Aug 25, 2022Aug 26, 2022 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
President and CEO
14,855$23.07$342.7K0Aug 25, 2022Aug 26, 2022 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
President and CEO
35,045$1.24$43.5K35,045Aug 24, 2022Aug 26, 2022 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
President and CEO
35,045$22.80$798.9K0Aug 24, 2022Aug 26, 2022 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
President and CEO
35,045——1,161,870Aug 24, 2022Aug 26, 2022 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
President and CEO
100$22.47$2.2K0Aug 15, 2022Aug 17, 2022 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
SALE
President and CEO
100——1,196,915Aug 15, 2022Aug 17, 2022 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASE
President and CEO
100$1.24$124100Aug 15, 2022Aug 17, 2022 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
1,004——3,896Jun 10, 2022Jun 13, 2022 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
4,340——4,340Jun 10, 2022Jun 13, 2022 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
425,000——425,000Jan 21, 2022Mar 15, 2022 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
3,269——3,269Jun 4, 2021Jun 7, 2021 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
630——2,892Jun 4, 2021Jun 7, 2021 ↗View →
RNA
ATRIUM THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
300,000——300,000Feb 2, 2021Feb 4, 2021 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
2,468——2,468Jun 10, 2020Jun 12, 2020 ↗View →
LGND
LIGAND PHARMACEUTICALS INC
PURCHASEGRANT
Stock grant
831——2,262Jun 10, 2020Jun 12, 2020 ↗View →
Other insiders · OABI
Loading peer insiders…
About this filer
CIK 0001629383
ROLE
Director
PRIMARY
OABI
COMPANIES
5
ACTIVE SINCE
Jun 2020
MARKETPEEL · /INSIDER/0001629383DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback